Sentence examples for mutation is now from inspiring English sources

The R506Q Factor V-Leiden mutation is now usually characterized using molecular biology, and this technique tends to become the first intention assay for characterization of patients.

Since one individual with this mutation is now 79 years old and shows no signs of disease, this mutation may be associated with a penetrance under 100%.

Since one individual with this mutation, who is the father of a clinically affected patient with T188K mutation, is now 79 years old and shows no signs of disease, this mutation is likely associated with a penetrance under 100%.

Testing for the presence of an IDH1/2 mutation is now considered by international guidelines for glioma management [ 29, 30].

Likewise in colorectal cancer, the presence of activating downstream KRAS mutations is associated with resistance to the anti-EGFR monoclonal antibody cetuximab, such that testing for this mutation is now recommended so that only those with wild-type KRAS are treated with cetuximab [ 11].

DSB-dependent, stress-induced mutation is now shown to occur both nonrandomly in time, preferentially coupled to stress by its dependence on stress-response activation (Ponder et al., 2005; Shee et al., 2011a), and nonrandomly in genomic space, causing hotspots close to DSB sites.

The effects of the P1332L mutation are now further discussed in the revised manuscript.

Testing for KRAS mutations is now being recommended as a tailored therapeutic strategy prior to anti-EGFR treatment; however, the low sensitivity of direct sequencing frequently leads to failure of detection of KRAS mutations in clinical samples.

The identification of point mutations is now straightforward owing to advances in sequencing technology and in mutation detection.

Determining fitness of specific mutations is now possible using macro-evolutionary inferences and population genetics approaches [ 71- 73], which can be successfully combined with genome-wide association studies [ 74].

Molecular screening for BRCA1 and BRCA2 mutations is now an established component of risk evaluation and management of familial breast cancer.